|
MAPK1IP1L expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.88490034481026E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.46490000527433E-09 |
| Normal-vs-Stage2 |
8.40290000025945E-07 |
| Normal-vs-Stage3 |
9.48390255217646E-11 |
| Normal-vs-Stage4 |
9.13091824372714E-12 |
| Stage1-vs-Stage2 |
9.676400E-01 |
| Stage1-vs-Stage3 |
5.787900E-02 |
| Stage1-vs-Stage4 |
5.361000E-03 |
| Stage2-vs-Stage3 |
2.311000E-01 |
| Stage2-vs-Stage4 |
9.171900E-02 |
| Stage3-vs-Stage4 |
4.625000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.39500000440052E-09 |
| Normal-vs-AfricanAmerican |
3.944300E-03 |
| Normal-vs-Asian |
3.63670005221195E-09 |
| Caucasian-vs-AfricanAmerican |
2.709200E-01 |
| Caucasian-vs-Asian |
5.741800E-01 |
| AfricanAmerican-vs-Asian |
2.005800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.2165003166208E-10 |
| Normal-vs-Female |
1.43010003839095E-09 |
| Male-vs-Female |
2.626400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.09900000211383E-08 |
| Normal-vs-Age(41-60Yrs) |
1.0547118733939E-13 |
| Normal-vs-Age(61-80Yrs) |
2.37750041875984E-10 |
| Normal-vs-Age(81-100Yrs) |
2.485600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.054600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.047200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.269600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.949000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.826800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.422000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.416320E-03 |
| Classical-VS-Follicular |
3.217200E-03 |
| Classical-VS-Other |
1.405810E-01 |
| Classical-VS-Normal |
6.59690000404112E-08 |
| Tall-VS-Follicular |
5.790200E-01 |
| Tall-VS-Other |
8.204600E-01 |
| Tall-VS-Normal |
9.86829506999243E-11 |
| Follicular-VS-Other |
7.009800E-01 |
| Follicular-VS-Normal |
2.74890110674164E-11 |
| Other-VS-Normal |
2.3456999999949E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.41289979715964E-10 |
| Normal-vs-N1 |
2.12500017582329E-11 |
| N0-vs-N1 |
2.347800E-01 |
|
|
